ALGS
Aligos Therapeutics, Inc.
There isn't enough reported data to score ALGS yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
ALGS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
ALGS's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
ALGS PE Valuation
ALGS has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
ALGS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong decline | |
| -- | |
| Limited | |
| Moderate |
Analysts expect ALGS's losses to shrink, with revenue declining.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
ALGS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2023 | -$46.75 | +$19.75 |
| Q2 2023 | -$47.50 | +$27.50 |
| Q1 2023 | -$48.50 | +$34.50 |
| Q4 2022 | -$56.25 | +$24.25 |
LLY has the stronger earnings trend. Trailing diluted EPS is down 142% for ALGS versus LLY up 51%.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.83 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY's earnings per share have climbed steadily: $30.81 over the past year, up 51% from the year before, and higher year over year for 11 quarters in a row.
ALGS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $2.8M | +282% |
| Q1 2026 | $2.8M | +810% |
| Q4 2025 | $169K | -72% |
| Q3 2025 | $741K | -41% |
| Q2 2025 | $965K | -9% |
| Q1 2025 | $311K | -55% |
| Q4 2024 | $606K | -9.8% |
| Q3 2024 | $1.3M | +15% |
ALGS's revenue is recovering but still below its 2023 peak: $3M last quarter, up 282% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -774% | +3054 points |
| Q1 2026 | -952% | +5236 points |
| Q4 2025 | -12908% | -9515 points |
| Q3 2025 | -3827% | -2217 points |
| Q2 2025 | -1924% | +566 points |
| Q1 2025 | -6187% | -3011 points |
| Q4 2024 | -3393% | +475 points |
| Q3 2024 | -1610% | +147 points |
ALGS's operating margin was −774% last quarter, up 1151 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over ALGS on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over ALGS on profitability, with a higher operating margin.
ALGS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1.5M | +$25.8M |
| Q2 2026 | -$25M | -$9.4M |
| Q1 2026 | -$23.1M | -$2.2M |
| Q3 2025 | -$24.3M | -$4.2M |
| Q2 2025 | -$15.5M | +$4M |
| Q1 2025 | -$20.9M | +$1.8M |
| Q3 2024 | -$20.1M | +$235K |
| Q2 2024 | -$19.5M | -$5.9M |
ALGS has burned cash in almost every quarter: −$68M over the past year, against −$81M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over ALGS on cash generation, producing positive trailing cash flow while its opponent burns cash.
ALGS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +31.1K shares |
| 1 year | +1.1% | +111K shares |
| 3 years | +513% | +8.8M shares |
ALGS has 10M diluted shares, up 1.1% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over ALGS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
ALGS Net Leverage
ALGS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
ALGS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 27.6 | Oversold |
| Stochastic | 8.1 | Oversold |
ALGS's weekly RSI is 28 (oversold) and its Stochastic is 8 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
ALGS PE vs Healthcare Sector
ALGS has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
ALGS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.61 | 57% below |
| 20 week MA | $5.29 | 63% below |
| 50 week MA | $6.56 | 70% below |
| 100 week MA | $9.83 | 80% below |
| 200 week MA | $15.4 | 87% below |
ALGS is in a downtrend: it's below all five of its weekly moving averages, and 87% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over ALGS on trend strength, trading above more of its moving averages.
ALGS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $371.3 | $721.3 | +94% |
| 2021 | $721.3 | $296.5 | -59% |
| 2022 | $296.5 | $22.7 | -92% |
| 2023 | $22.7 | $16.6 | -27% |
| 2024 | $16.6 | $41.2 | +148% |
| 2025 | $41.2 | $10.1 | -75% |
| 2026 YTD | $10.1 | $1.98 | -80% |
ALGS's yearly returns have swung widely, from +148% in 2024 to −92% in 2022. It's down 80% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over ALGS on returns for 2026, with the stronger performance.